FIG. 3.

BIM-22493 ameliorates insulin resistance in obese NHP. Fasting insulin levels (A) and homeostasis model assessment insulin resistance (HOMA-IR) (B) in diet-sensitive animals is dramatically decreased during BIM-22493 treatment and is maintained for 4 weeks after cessation of treatment compared with vehicle (Veh). Wash, washout. *P < 0.05, **P < 0.005 compared with control by repeated-measures ANOVA with Dunnett post hoc testing. C: Insulin release in response to an IVGTT is reduced in obese NHP treated with BIM-22493, as measured by area under the curve (AUC). *P < 0.01, **P < 0.0001 by repeated-measures ANOVA with Dunnett post hoc testing. D: Glucose clearance as measured by AUC was significantly improved in response to an IVGTT. *P < 0.05 by repeated-measures ANOVA with Dunnett post hoc testing.